DURHAM, N.C. --(BUSINESS WIRE)--Feb. 12, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

DURHAM, N.C. --(BUSINESS WIRE)--Feb. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

- Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to Extend Precision’s Cash Runway into the First Half of 2026 and Fund Precision’s Wholly-Owned In Vivo

- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study DURHAM, N.C. --(BUSINESS WIRE)--Dec. 13, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary

- Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity - mitoARCUS efficiently shifted m.3243A>G heteroplasmy without off-target activity, leading to an overall improvement in mitochondrial

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

- PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA - Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at maximal on-target editing dose - PBGENE-HBV final clinical candidate ready with CTA and/or IND

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Company to Host Webcast and Conference Call on Monday, November 13, 2023 at 4:30 PM ET DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing

- Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 - Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline - Expanded portfolio with PBGENE-PMM as a potentially curative treatment for m.3243 associated primary mitochondrial

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

- ARCUS showed durable, high-efficiency gene insertion capabilities in NHPs and comparison to CRISPR-Cas9 - Data demonstrates ability of ARCUS to achieve large gene excisions enabling significant functional muscle improvement in a   DMD mouse model DURHAM, N.C. --(BUSINESS WIRE)--Oct.

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 23, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 12, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,